- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Corzyna, Ranexa
Synonyms :
ranolazine
Class :
Anti-anginal agent
Dosage Forms & Strengths
Tablet extended release, Oral:
500 mg
1000 mg
Chronic:
500
mg
Oral
twice a day
Tablet
increase to 1000 mg tablet twice a day only if needed
500 - 1000
mg
Oral
every 12 hrs
Tablet
No safe and efficacious dosing is available
Refer to adult dosing
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
ranolazine: they may enhance the serum concentration of CYP3A4 Inducers
ranolazine: they may enhance the serum concentration of CYP3A4 Inducers
ranolazine: they may enhance the serum concentration of CYP3A4 Inducers
ranolazine: they may enhance the serum concentration of CYP3A4 Inducers
ranolazine: they may enhance the serum concentration of CYP3A4 Inducers
may enhance the serum concentration when combined
may enhance the serum concentration of metformin
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
It may enhance the levels when combined with rosiglitazone by diminishing the elimination
nafcillin will decrease the effect of action of ranolazine by affecting enzyme CYP3A4 metabolism.
the effect of ranolazine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of ranolazine by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ranolazine
when used together, entrectinib and ranolazine both increase the QTc interval
when used together, encorafenib and ranolazine both increase the QTc interval
metronidazole enhances the effect of ranolazine by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may increase the QTc interval when combined
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may diminish the serum concentration of CYP3A4 Inducers
it increases the toxicity of angiotensin II receptor blockers
it increases the toxicity of angiotensin II receptor blockers
it increases the toxicity of angiotensin II receptor blockers
it increases the toxicity of angiotensin II receptor blockers
it increases the toxicity of angiotensin II receptor blockers
It may enhance toxicity when combined with cholic acid by diminishing the elimination
it may diminish the excretion rate when combined with gadofosveset, resulting in an enhanced serum level
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
CYP3A4 inhibitors increase the concentration of ranolazine in serum
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
it may increase the toxicity of each other
may enhance the serum concentration
may enhance the serum concentration
it increases the concentration of metformin in the serum
Frequency defined:
>10%
Headache
Dizziness
Blurred vision
1% to 10%
Bradycardia
Abdominal pain
Diarrhea
Dyspepsia
Nausea
Vomiting
Asthenia
Skin photosensitivity
Back pain
Postmarketing
Atrial flutter
Heart failure
Anaphylaxis
Angioedema
Pregnancy consideration: Few adverse effects were reported in animal reproductive studies. Contradicted for pregnant women.
Lactation: ranolazine excretion in breast milk is not known.
Pregnancy category:
Patient information leaflet
Generic Name: Ranolazine
Pronounced: ranolazine
Why do we use ranolazine?
Ranolazine is used for the treatment of chronic angina, fetal tachycardia, and ventricular arrhythmias.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
